Metronomic per oral decitabine-cedazuridine plus venetoclax in acute myeloid leukemia
To the EditorAcute myeloid leukemia (AML) is a biologically heterogeneous and clinically aggressive hematologic malignancy, with a median age at diagnosis of approximately 70 years [1–3]. Increasin...
Authors
- Morten Yung Isaksen (ORCID: https://orcid.org/0009-0001-0569-2929)
- Øystein Halvorsen
- Nessar Ahmad Azrakhsh (ORCID: https://orcid.org/0000-0002-4374-8882)
- Irini Ktoridou-Valen (ORCID: https://orcid.org/0009-0008-1801-7085)
- Pål Tore Bentsen (ORCID: https://orcid.org/0009-0002-9865-8902)
- Håkon Reikvam (ORCID: https://orcid.org/0000-0001-5439-8411)
- Astrid Marta Olsnes (ORCID: https://orcid.org/0000-0001-7249-8272)
- Bjørn Tore Gjertsen (ORCID: https://orcid.org/0000-0001-9358-9704)
- O. Nyquist (ORCID: https://orcid.org/0009-0005-2776-3686)
- Ragnhild Frøyen
Institutions
- Haukeland University Hospital (NO)
- Sykehuset i Vestfold (NO)
- University of Bergen (NO)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2026-10-28
- DOI
- https://doi.org/10.1080/10428194.2026.2740250
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00